ZA200900350B - Immediate-release tablet formulations of a thrombin receptor antagonist - Google Patents
Immediate-release tablet formulations of a thrombin receptor antagonistInfo
- Publication number
- ZA200900350B ZA200900350B ZA200900350A ZA200900350A ZA200900350B ZA 200900350 B ZA200900350 B ZA 200900350B ZA 200900350 A ZA200900350 A ZA 200900350A ZA 200900350 A ZA200900350 A ZA 200900350A ZA 200900350 B ZA200900350 B ZA 200900350B
- Authority
- ZA
- South Africa
- Prior art keywords
- immediate
- receptor antagonist
- release tablet
- tablet formulations
- thrombin receptor
- Prior art date
Links
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000007916 tablet composition Substances 0.000 title 1
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81782106P | 2006-06-30 | 2006-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200900350B true ZA200900350B (en) | 2010-01-27 |
Family
ID=38895141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200900350A ZA200900350B (en) | 2006-06-30 | 2009-01-15 | Immediate-release tablet formulations of a thrombin receptor antagonist |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20080031943A1 (xx) |
| EP (2) | EP2034969B1 (xx) |
| JP (2) | JP5116764B2 (xx) |
| KR (1) | KR20090023670A (xx) |
| CN (2) | CN104922054A (xx) |
| AR (1) | AR061790A1 (xx) |
| AU (1) | AU2007269733B2 (xx) |
| BR (1) | BRPI0713935A2 (xx) |
| CA (1) | CA2656395C (xx) |
| CL (1) | CL2007001923A1 (xx) |
| CO (1) | CO6150126A2 (xx) |
| ES (2) | ES2616354T3 (xx) |
| MX (1) | MX2009000131A (xx) |
| NO (1) | NO20090467L (xx) |
| PE (1) | PE20080376A1 (xx) |
| TW (1) | TWI367112B (xx) |
| WO (1) | WO2008005353A2 (xx) |
| ZA (1) | ZA200900350B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
| US8624050B2 (en) * | 2007-06-22 | 2014-01-07 | General Electric Company | Solution process for transparent conductive oxide coatings |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| SI2438060T1 (sl) | 2009-06-04 | 2014-04-30 | Merck Sharp & Dohme Corp. | Aktivni metabolit trombin receptorskega antagonista |
| MX2011013091A (es) | 2009-06-08 | 2012-01-12 | Schering Corp | Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel. |
| CN102442965B (zh) * | 2010-09-30 | 2013-12-11 | 天津药物研究院 | 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途 |
| WO2017134200A1 (en) | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
| TR201601548A2 (tr) | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
| MX2020008137A (es) * | 2018-02-02 | 2020-10-19 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | Formulaciones orales y usos de las mismas. |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61137813A (ja) * | 1984-12-07 | 1986-06-25 | Sawai Seiyaku Kk | 持続性セフラジン製剤 |
| JPS63162620A (ja) * | 1986-12-25 | 1988-07-06 | Teisan Seiyaku Kk | 遅溶性顆粒及びそれを用いた持続性複合顆粒 |
| GB9414045D0 (en) * | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| US20010003588A1 (en) * | 1996-09-12 | 2001-06-14 | Smithkline Beecham Corporation | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
| JPH10130142A (ja) * | 1996-10-31 | 1998-05-19 | Zensei Yakuhin Kogyo Kk | 放出持続型圧縮製剤 |
| JPH10298062A (ja) * | 1997-04-24 | 1998-11-10 | Pfizer Pharmaceut Co Ltd | 口腔内速溶型錠剤 |
| KR100393492B1 (ko) * | 1997-11-25 | 2003-08-02 | 쉐링 코포레이션 | 트롬빈 수용체 길항제 |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US6630451B1 (en) | 1999-06-29 | 2003-10-07 | Orthomcneil Pharmaceutical, Inc. | Benzimidazolone peptidometics as thrombin receptor antagonist |
| US6858577B1 (en) | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
| WO2001000656A2 (en) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| ES2291323T3 (es) | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
| ATE282041T1 (de) * | 2001-02-23 | 2004-11-15 | Ortho Mcneil Pharm Inc | Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist |
| ATE538090T1 (de) | 2001-04-19 | 2012-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 2-iminopyrrolidin- derivaten |
| MXPA04003610A (es) * | 2001-10-18 | 2004-07-27 | Schering Corp | Analogos de himbacina como antagonistas del receptor de trombina. |
| JP4558331B2 (ja) * | 2002-04-16 | 2010-10-06 | シェーリング コーポレイション | 三環式トロンビンレセプターアンタゴニスト |
| DE10317816A1 (de) | 2003-04-16 | 2004-11-04 | Claas Selbstfahrende Erntemaschinen Gmbh | Feldhäcksler mit positionierbarer Fahrerkabine |
| CZ300438B6 (cs) * | 2003-11-25 | 2009-05-20 | Pliva Hrvatska D.O.O. | Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu |
| CN101384259A (zh) * | 2005-12-22 | 2009-03-11 | 先灵公司 | 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂 |
| AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
| EP2037909A2 (en) * | 2006-06-30 | 2009-03-25 | Schering Corporation | Solid dose formulations of a thrombin receptor antagonist |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
| MX2009010268A (es) * | 2007-03-23 | 2009-11-09 | Schering Corp | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. |
-
2007
- 2007-06-28 TW TW096123547A patent/TWI367112B/zh not_active IP Right Cessation
- 2007-06-29 EP EP07796595.2A patent/EP2034969B1/en active Active
- 2007-06-29 EP EP12159636.5A patent/EP2491922B1/en active Active
- 2007-06-29 CN CN201510409546.7A patent/CN104922054A/zh active Pending
- 2007-06-29 CA CA2656395A patent/CA2656395C/en active Active
- 2007-06-29 ES ES12159636.5T patent/ES2616354T3/es active Active
- 2007-06-29 AR ARP070102934A patent/AR061790A1/es not_active Application Discontinuation
- 2007-06-29 MX MX2009000131A patent/MX2009000131A/es unknown
- 2007-06-29 ES ES07796595.2T patent/ES2616405T3/es active Active
- 2007-06-29 CN CNA2007800325694A patent/CN101511345A/zh active Pending
- 2007-06-29 BR BRPI0713935-7A patent/BRPI0713935A2/pt not_active IP Right Cessation
- 2007-06-29 WO PCT/US2007/015168 patent/WO2008005353A2/en not_active Ceased
- 2007-06-29 CL CL200701923A patent/CL2007001923A1/es unknown
- 2007-06-29 AU AU2007269733A patent/AU2007269733B2/en not_active Ceased
- 2007-06-29 JP JP2009518301A patent/JP5116764B2/ja not_active Expired - Fee Related
- 2007-06-29 US US11/771,520 patent/US20080031943A1/en not_active Abandoned
- 2007-06-29 KR KR1020097000084A patent/KR20090023670A/ko not_active Withdrawn
- 2007-07-02 PE PE2007000840A patent/PE20080376A1/es not_active Application Discontinuation
-
2009
- 2009-01-15 ZA ZA200900350A patent/ZA200900350B/xx unknown
- 2009-01-29 NO NO20090467A patent/NO20090467L/no not_active Application Discontinuation
- 2009-01-30 CO CO09008875A patent/CO6150126A2/es unknown
-
2012
- 2012-03-30 JP JP2012082021A patent/JP2012126752A/ja not_active Withdrawn
-
2016
- 2016-03-10 US US15/066,726 patent/US20170224666A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008005353A2 (en) | 2008-01-10 |
| AU2007269733B2 (en) | 2013-02-21 |
| EP2034969A2 (en) | 2009-03-18 |
| CN101511345A (zh) | 2009-08-19 |
| PE20080376A1 (es) | 2008-06-13 |
| JP5116764B2 (ja) | 2013-01-09 |
| AU2007269733A1 (en) | 2008-01-10 |
| EP2491922B1 (en) | 2017-01-04 |
| US20080031943A1 (en) | 2008-02-07 |
| ES2616405T3 (es) | 2017-06-13 |
| TWI367112B (en) | 2012-07-01 |
| CO6150126A2 (es) | 2010-04-20 |
| CA2656395C (en) | 2016-12-13 |
| CA2656395A1 (en) | 2008-01-10 |
| CN104922054A (zh) | 2015-09-23 |
| TW200810792A (en) | 2008-03-01 |
| BRPI0713935A2 (pt) | 2012-12-04 |
| JP2012126752A (ja) | 2012-07-05 |
| MX2009000131A (es) | 2009-01-26 |
| JP2009542678A (ja) | 2009-12-03 |
| KR20090023670A (ko) | 2009-03-05 |
| US20170224666A9 (en) | 2017-08-10 |
| EP2491922A1 (en) | 2012-08-29 |
| EP2034969B1 (en) | 2017-01-11 |
| WO2008005353A3 (en) | 2008-06-26 |
| CL2007001923A1 (es) | 2008-02-08 |
| US20160193196A1 (en) | 2016-07-07 |
| NO20090467L (no) | 2009-03-19 |
| AR061790A1 (es) | 2008-09-24 |
| ES2616354T3 (es) | 2017-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200900350B (en) | Immediate-release tablet formulations of a thrombin receptor antagonist | |
| HUS2100003I1 (hu) | Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja | |
| HUS2400046I1 (hu) | Specifikus endotelin receptor antagonistát és PDE5-inhibitort tartalmazó terápiás készítmények | |
| IL198869A0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDGFRa ANTAGONIST | |
| ZA200810164B (en) | Sustained release pharmaceutical dosage form containing phenylphrine | |
| PL2079688T3 (pl) | Antagoniści receptora glukagonu, kompozycje zawierające takie związki oraz ich zastosowanie farmaceutyczne | |
| EP1945197A4 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING A BETA ADRENE RECEPTOR ANTAGONIST WITH EXTENDED RELEASE | |
| EP2133096A4 (en) | IN THE MOUTHING TABLET | |
| PL2399579T3 (pl) | Farmaceutyczne postacie dawkowania | |
| EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| IL194355A0 (en) | Orally disintegrating tablets | |
| PL2034970T3 (pl) | Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę | |
| EP2112925A4 (en) | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS | |
| IL204528A (en) | Pharmaceutical dosage forms for immediate sustained release of metadoxin | |
| IL198780A0 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
| EP2191830A4 (en) | SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST | |
| ZA200902592B (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| SI2040684T1 (sl) | Večenotne tablete | |
| EP2211843B8 (en) | Pharmaceutical moire pill | |
| EP2075252A4 (en) | NK1 Receptor Antagonists COMPOSITION | |
| EP2211847A4 (en) | PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE | |
| GB2458593B (en) | Anthelmintic tablet formulations | |
| GB0605104D0 (en) | Tablet dispenser | |
| HK1126964A (en) | Immediate-release tablet formulations of a thrombin receptor antagonist | |
| GB0608465D0 (en) | Tablet dispenser |